News stories about PDL BioPharma (NASDAQ:PDLI) have been trending somewhat positive on Thursday, according to Accern. The research group identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. PDL BioPharma earned a daily sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.3468201896545 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several analysts have issued reports on the company. Piper Jaffray Companies restated a “buy” rating and set a $4.00 price objective on shares of PDL BioPharma in a research note on Thursday, August 10th. BidaskClub upgraded PDL BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research upgraded PDL BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Wednesday, August 16th. Finally, ValuEngine upgraded PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Friday, August 4th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $3.50.
Shares of PDL BioPharma (PDLI) remained flat at $3.46 during mid-day trading on Thursday. 1,328,570 shares of the company were exchanged. The company has a market cap of $533.12 million, a PE ratio of 7.95 and a beta of 0.49. The stock has a 50 day moving average of $3.23 and a 200 day moving average of $2.58. PDL BioPharma has a 52-week low of $1.93 and a 52-week high of $3.77.
PDL BioPharma (NASDAQ:PDLI) last released its earnings results on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.17. PDL BioPharma had a return on equity of 9.07% and a net margin of 23.03%. The business had revenue of $143.80 million for the quarter, compared to the consensus estimate of $56.30 million. During the same period last year, the business earned $0.09 earnings per share. The firm’s revenue for the quarter was up 584.8% compared to the same quarter last year. On average, analysts anticipate that PDL BioPharma will post $0.61 EPS for the current year.
PDL BioPharma announced that its board has authorized a share repurchase program on Monday, September 25th that permits the company to buyback $25.00 million in outstanding shares. This buyback authorization permits the biotechnology company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.